Compare Summit Therapeutics Inc (SMMT) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Synchrony Financial — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.98B), while Synchrony Financial trades at $77.79 (market cap $25.17B). The key difference: Synchrony Financial is the larger of the two by market cap, and Synchrony Financial pays a 1.76% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | SYF | |
|---|---|---|
Market Cap | $13.98B | $25.17B |
Sector | Health | Financials |
52-Week High | $26.38 | $88.47 |
52-Week Low | $12.43 | $63.78 |
Enterprise Value | $13.31B | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.
Synchrony Financial (SYF) trades at $78.62, down 1.63% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a low P/E of 7.93 and a robust ROE of 22.23%, supported by three consecutive quarterly earnings beats. Recent developments include a strategic partnership with OpenAI to enhance AI-driven commerce, announced on August 17, 2026, and a dividend payment scheduled for August 17, 2026.
The outlook is positive, with a consensus price target of $87.33 suggesting 11% upside. Key opportunities include earnings momentum and AI innovation, while risks involve consumer credit deterioration and investing cash flow turning negative in 2026. Analyst sentiment is bullish, with 62.5% recommending buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
